EXHIBIT A

 

JOINT FILING AGREEMENT

 

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to shares of common stock, par value $0.001 per share of Inhibikase Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.

 

In evidence thereof, the undersigned, being duly authorized, have executed this Joint Filing Agreement as of February 14, 2025.

 

  ADAR1 CAPITAL MANAGEMENT, LLC
   
  /s/ Daniel Schneeberger
  Daniel Schneeberger
  Manager
   
  ADAR1 CAPITAL MANAGEMENT GP, LLC
   
  /s/ Daniel Schneeberger
  Daniel Schneeberger
  Manager
   
  /s/ Daniel Schneeberger
  Daniel Schneeberger, in his individual capacity

 

 

 

Inhibikase Therapeutics (NASDAQ:IKT)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Inhibikase Therapeutics 차트를 더 보려면 여기를 클릭.
Inhibikase Therapeutics (NASDAQ:IKT)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Inhibikase Therapeutics 차트를 더 보려면 여기를 클릭.